Inspec

Inspec Debt/EBITDA

The Total Debt to EBITDA Ratio of Inspec (6656.T) as of Nov 13, 2026 is 14.12. In the previous year, Total Debt to EBITDA Ratio was 14.19 — a change of -0.53% (lower).

Debt/EBITDA

14.12

YoY

-0.53%

Last updated:

Total Debt to EBITDA Ratio of Inspec is 2026 14.12 . Total Debt to EBITDA Ratio of Inspec was 2025 14.19 . It decreases by -0.53% lower compared to the previous year.

The Inspec Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2019
2.72 JPY
Jan 1, 2020
8.38 JPY
Jan 1, 2021
-5.09 JPY
Jan 1, 2022
59.00 JPY
Jan 1, 2023
13.82 JPY
Jan 1, 2024
-10.60 JPY
Jan 1, 2025
14.19 JPY
Jan 1, 2026
14.12 JPY
The Inspec Debt/EBITDA history
YEARDebt/EBITDAYoY
14.12-0.53%
14.19-233.92%
-10.60-176.71%
13.82-76.58%
59.00-1,259.91%
-5.09-160.73%
8.38+208.31%
2.72-149.93%
-5.44-202.94%
5.29-110.97%
-48.20-590.04%
9.84+5.69%
9.31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

Total Debt to EBITDA Ratio of Inspec is 14.12 in 2026.

Total Debt to EBITDA Ratio of Inspec changed from 14.19 to 14.12, representing a -0.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Inspec since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Inspec with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Inspec

All Key Metrics — Inspec